IL1B and neoplasm: In mice, a novel Ly6C-negative MDSC subset has been reported to target NK cells after activation by tumor-released IL-1β [154,155], whereas in melanoma patients, M-MDSC are activated by PGE2 and impair NK cell-mediated cytotoxicity through the release of TGF-β [117].